Apr 13, 2016 — Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had myelodysplastic syndrome ... fe9c53e484 lortain
https://wakelet.com/wake/PHlvO8VYmFzG9PwYY3O7r
https://wakelet.com/wake/wN6s5HCFrT536SydHLpoQ
https://wakelet.com/wake/86D7NEuFtumnqr8Zi9v1b
https://wakelet.com/wake/-cpXjPkk2LL-97KHJm6hi
https://wakelet.com/wake/YDjD8VA7fy1UAh7gvIDb5
Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-​dependent lower-risk myelodysplastic syndrome (MDS) patients. · Authors: · Research ...
Like
Comment
Share
